Revuforj (revumenib) — United Healthcare
relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation
Initial criteria
- Diagnosis of acute leukemia
- Disease is relapsed or refractory
- Positive for lysine methyltransferase 2A gene (KMT2A) translocation
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Revuforj therapy
Approval duration
12 months